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Abstract
Background
At the beginning of June 2020, there were nearly 7 million reported cases of coronavirus
disease 2019 (COVID-19) worldwide and over 400,000 deaths in people with COVID-19.
The objective of this study was to determine associations between comorbidities listed in
the Charlson comorbidity index and mortality among patients in the United States with
COVID-19.
Methods and findings
A retrospective cohort study of adults with COVID-19 from 24 healthcare organizations in
the US was conducted. The study included adults aged 18–90 years with COVID-19 coded
in their electronic medical records between January 20, 2020, and May 26, 2020. Results
were also stratified by age groups (<50 years, 50–69 years, or 70–90 years). A total of
31,461 patients were included. Median age was 50 years (interquartile range [IQR], 35–63)
and 54.5% (n = 17,155) were female. The most common comorbidities listed in the Charlson
comorbidity index were chronic pulmonary disease (17.5%, n = 5,513) and diabetes mellitus
(15.0%, n = 4,710). Multivariate logistic regression analyses showed older age (odds ratio
[OR] per year 1.06; 95% confidence interval [CI] 1.06–1.07; p < 0.001), male sex (OR 1.75;
95% CI 1.55–1.98; p < 0.001), being black or African American compared to white (OR 1.50;
95% CI 1.31–1.71; p < 0.001), myocardial infarction (OR 1.97; 95% CI 1.64–2.35; p <
0.001), congestive heart failure (OR 1.42; 95% CI 1.21–1.67; p < 0.001), dementia (OR
1.29; 95% CI 1.07–1.56; p = 0.008), chronic pulmonary disease (OR 1.24; 95% CI 1.08–
1.43; p = 0.003), mild liver disease (OR 1.26; 95% CI 1.00–1.59; p = 0.046), moderate/
severe liver disease (OR 2.62; 95% CI 1.53–4.47; p < 0.001), renal disease (OR 2.13; 95%
CI 1.84–2.46; p < 0.001), and metastatic solid tumor (OR 1.70; 95% CI 1.19–2.43; p =
0.004) were associated with higher odds of mortality with COVID-19. Older age, male sex,
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and being black or African American (compared to being white) remained significantly asso-
ciated with higher odds of death in age-stratified analyses. There were differences in which
comorbidities were significantly associated with mortality between age groups. Limitations
include that the data were collected from the healthcare organization electronic medical
record databases and some comorbidities may be underreported and ethnicity was
unknown for 24% of participants. Deaths during an inpatient or outpatient visit at the partici-
pating healthcare organizations were recorded; however, deaths occurring outside of the
hospital setting are not well captured.
Conclusions
Identifying patient characteristics and conditions associated with mortality with COVID-19 is
important for hypothesis generating for clinical trials and to develop targeted intervention
strategies.
Author summary
Why was this study done?
• Coronavirus disease 2019 (COVID-19) has led to a public health emergency
internationally.
• As of June 2020, there were over 400,000 deaths reported with COVID-19 globally and
over 110,000 deaths were in the US, but many people have also recovered.
• Because of the unprecedented outbreak of COVID-19 worldwide, little is known about
which underlying health conditions may impact a person’s likelihood of dying with
COVID-19.
• Some previous studies have suggested being older; being from a black, Asian, or minor-
ity ethnic (BAME) background; and having certain health conditions may increase risk
of death with COVID-19, but further evidence is needed to understand factors which
influence this.
What did the researchers do and find?
• The research utilized a network of 24 healthcare organizations in the US, which pro-
vided deidentified data from electronic medical records of patients.
• A total of 31,461 adults with COVID-19 coded in their electronic medical records were
included in the study after a search of the network between January 20, 2020, and May
26, 2020.
• We determined associations between age, sex, ethnicity, comorbidities, and death with
COVID-19 during the study period.
• After accounting for the other included factors in the study, being older, being male,
being black or African American, and having a history of myocardial infarction,
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congestive heart failure, dementia, chronic pulmonary disease, mild liver disease, mod-
erate/severe liver disease, renal disease, or metastatic solid tumor were all associated
with higher odds of death with COVID-19.
• There were differences in which comorbidities were associated with death when we
stratified the results by age group.
What do these findings mean?
• Identifying factors associated with death with COVID-19 could help with hypothesis
generating for clinical trials and identify patients who may need to be targeted for early
intervention or monitoring.
• The study has limitations; for example, some health conditions may be underreported
or incorrectly coded in electronic medical records at the time of data entry, and all
deaths of participants may not have been captured.
Introduction
Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019
[1]. Subsequently, COVID-19 was declared a Public Health Emergency of International Con-
cern on January 30, 2020, by the World Health Organization. The first confirmed case of
COVID-19 reported in the US was in Washington state on January 20, 2020 [2]. At the begin-
ning of June 2020, 213 countries and territories had reported almost 7 million cases of
COVID-19, with over 400,000 deaths reported with COVID-19 and over 110,000 deaths in the
US alone [3].
An emerging evidence base has started to identify factors that associate with adverse out-
comes for people with COVID-19. Older age is the most consistent risk factor for severity of
COVID-19 that has emerged from the literature so far [4–6]. There is some evidence to suggest
being male, black or African American ethnicity, or from certain ethnic minority backgrounds
or having a history of conditions including cardiovascular or cerebrovascular diseases, hyper-
tension, diabetes mellitus, or chronic kidney disease is associated with increased COVID-19
severity and/or mortality [5, 7–12].
More studies are needed to determine associations between comorbidities and outcomes
for patients with COVID-19. Multimorbidity is closely linked to frailty status [13], which is
used in decision-making for critical care admission [14]. The objective of the study was to
determine associations between age, sex, ethnicity, comorbidities, and mortality of adults with
COVID-19 in the US.
Methods
The study used data from TriNetX, a global federated health research network that provided
an anonymized dataset of electronic medical records (EMRs). The TriNetX network was
searched on June 9, 2020, and a deidentified dataset of patients with COVID-19 aged up to 90
years identified in EMRs between January 20, 2020, and May 26, 2020, was provided. The data
on the research network come from academic medical centers, specialty physician practices,
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and community hospitals. Further details about TriNetX processes and standardization of data
are in S1 Text.
Patients with COVID-19 were identified following criteria provided by TriNetX based on
Centers for Disease Control and Prevention (CDC) coding guidelines [15]. Patients were
included if they had 1 or more of the following International Classification of Diseases, Ninth
Revision and Tenth Revision, Clinical Modification (ICD-10-CM) codes in their EMRs: U07.1
COVID-19; B97.29 Other coronavirus as the cause of diseases classified elsewhere; B34.2 Coro-
navirus infection, unspecified; or a positive test result identified with COVID-19-specific labo-
ratory Logical Observation Identifiers Names and Codes (LOINCs). The code U07.2 COVID-
19, virus not identified, was also searched for, but no patients were found to have this code
recorded. Patients with ICD-9 code 079.89 were excluded to reduce the likelihood of patients
with false positive COVID-19 because this code may still be used occasionally as a "catch-all”
code for >50 viral infections.
The study included all patients with COVID-19 recorded in their EMRs from participating
healthcare organizations. This included both inpatient and outpatient care settings, but the
type of visit was not well recorded. History of comorbidities listed in the Charlson comorbidity
index were identified if the patient had a corresponding ICD code for the condition since Jan-
uary 1, 2015, in their EMRs captured in TriNetX [16]. The timeframe was chosen based on a
previous study that examined comorbidities in a 5-year interval [17]. Deaths during an inpa-
tient or outpatient visit at the participating healthcare organizations were recorded; however,
deaths occurring outside of the hospital setting are not well captured. As date of death was not
available in the downloaded deidentified dataset from TriNetX, we estimated date of death
based on the most recent date recorded in the patient EMRs from the following: diagnosis
(date), procedure (date), encounter (end date), vital signs (date), medication (start date). We
estimated time to mortality following COVID-19 using the estimated date of death minus the
first recording of COVID-19 in the EMRs (either from a positive laboratory test result or ICD-
10-CM code).
Descriptive statistics included proportions for categorical variables and medians and inter-
quartile ranges (IQRs) for continuous variables. Unadjusted and multivariate logistic regres-
sions were performed to explore associations between age, sex, ethnicity, comorbidities, and
mortality. Any deaths during the study period captured in EMRs of the participating health-
care organizations were included in the analysis. Variables identified as statistically significant
predictors with a significance level of p< 0.05 were planned to be inserted into a forward mul-
tivariate logistic model. All variables were statistically significant in unadjusted analysis and
inserted to the multivariate model, apart from in age-stratified analyses. No imputations were
made for missing data. Data were requested from TriNetX and all analyses were conducted
with Stata v.14.0.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines (S1 STROBE Checklist) [18]. No published prospective
analysis plan was produced. Analyses were planned prior to download of the study data from
TriNetX. Upon receipt of the data, we were informed that date of death was not available,
because of data privacy agreements, and therefore planned Cox proportional hazard models
were changed to logistic regression models. We also changed the search to only include people
with COVID-19 coded in their EMRs 2 weeks before the search date, to allow a 2-week time
window for potential follow-up and to be comparable with a cohort study which examined
comorbidities and mortality with COVID-19 in the United Kingdom [19]. We further limited
analyses to people aged 18 years or over and performed age-stratified analyses. We did not
impose any further exclusion criteria to limit selection bias.
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Ethics statement
No ethical approval was obtained, as no patient identifiable information was received and the
data were analyzed anonymously.
Results
In total 33,488 patients from 24 healthcare organizations had 1 or more of the specified
COVID-19 codes or a positive laboratory test in their EMRs during the study period. Patients
in the cohort were distributed between the 4 large Census Bureau–designated regions of the
US as follows: 27% (n = 9,040) in the Northeast, 21% (n = 6,898) in the Midwest, 30%
(n = 10,192) in the South, 21% (n = 7,181) in the West, and 0.5% (n = 177) unknown. Of the
patients identified, 50.3% (n = 16,833) were identified from ICD codes only (U07.1, B97.29, or
B34.2); 15.2% (n = 5,096) were identified from the ICD codes B97.29 or B34.2 only.
Of the total number of patients, 2.0% (n = 670) did not have age or sex recorded within the
TriNetX network and were excluded from analyses. A further 1,357 patients were aged<18
years and were also excluded. Therefore, 31,461 patients were included in analyses. The
median (IQR) age was 50 (35–63) years and 54.5% (n = 17,155) were female. In total, 45.2%
(n = 14,225) of participants were white, according to their EMRs, and 27.8% (n = 8,758) were
black or African American; smaller proportions of people from other ethnicities were identi-
fied, and ethnicity was unknown for 23.8% (n = 7,476). Of the total cohort, 59.5% (18,734) of
patients did not have a record of any of the comorbidities listed in the Charlson comorbidity
index; 17.4% (n = 5,458) had 1 comorbidity listed, 7.9% (n = 2,473) had 2 comorbidities, and
15.2% (n = 4,796) had�3 comorbidities. The most common comorbidities were chronic pul-
monary disease (17.5%, n = 5,513) and diabetes mellitus (15.0%, n = 4,710) (Table 1).
Of the 31,461 patients, 5.3% (n = 1,669) had no end date recorded on a healthcare organiza-
tion encounter during the study period and therefore may have not yet been discharged. The
median (IQR) estimated time in the study was 54 days (36–68). During the study period, 4.1%
(n = 1,296) patients were recorded as deceased, and the estimated median (IQR) time to mor-
tality after first recording of COVID-19 was 9 days (4–17). Of the total patient cohort, 4.1%
(n = 1,296) had a procedure code indicating invasive mechanical ventilation during the study
period in EMRs. Of the patients who died, 49.5% (n = 642) had a procedure code for invasive
mechanical ventilation compared to 2.2% (n = 654) of patients who were not recorded as
deceased.
In unadjusted analyses, the following variables were associated with higher odds of death:
older age, male sex, being black or African American compared to white, and all comorbidities
investigated (Table 2). Being Asian or having unknown ethnicity compared to being white was
associated with lower odds of death. On multivariate analyses, higher odds of death were asso-
ciated with older age (odds ratio [OR] per year 1.063; 95% confidence interval [CI] 1.058–
1.068; p< 0.001), male sex (OR 1.75; 95% CI 1.55–1.98; p< 0.001), being black or African
American compared to white (OR 1.50; 95% CI 1.31–1.71; p< 0.001), myocardial infarction
(OR 1.97; 95% CI 1.64–2.35; p< 0.001), congestive heart failure (OR 1.42; 95% CI 1.21–1.67;
p< 0.001), dementia (OR 1.29; 95% CI 1.07–1.56; p = 0.008), chronic pulmonary disease (OR
1.24; 95% CI 1.08–1.43; p = 0.003), mild liver disease (OR 1.26; 95% CI 1.00–1.59; p = 0.046),
moderate/severe liver disease (OR 2.62; 95% CI 1.53–4.47; p< 0.001), renal disease (OR 2.13;
95% CI 1.84–2.46; p< 0.001), and metastatic solid tumor (OR 1.70; 95% CI 1.19–2.43;
p = 0.004). Being native Hawaiian or other Pacific Islander was associated with higher odds of
death compared to being white, but there were only 115 people identified as native Hawaiian
or other Pacific Islander in this cohort. Having an unknown ethnicity was associated with
reduced odds of death compared to being white (OR 0.74; 95% CI 0.60–0.90, p = 0.003).
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Age-stratified analyses
Differences between age groups were found when results were stratified by age group (<50
years, 50–69 years, or 70–90 years). For all age groups, older age, being male, and being black
or African American compared to being white were associated with higher odds of death in
Table 1. Baseline characteristics of patients with COVID-19 in the TriNetX research network as of May 26, 2020.
Characteristics All participants
(n = 31,461)
Deceased
(n = 1,296)
Alive
(n = 30,165)
Age, median (IQR), years 50 (35–63) 72 (63–80) 49 (35–62)
<50 49.5 (15,578) 8.0 (104) 51.3 (15,474)
50–59 18.6 (5,855) 11.2 (145) 18.9 (5,710)
60–69 15.4 (4,843) 22.0 (285) 15.1 (4,558)
70–79 9.6 (3,015) 30.8 (399) 8.7 (2,616)
80–90 6.9 (2,170) 28.0 (363) 6.0 (1,807)
Sex
Female 54.5 (17,155) 41.1 (532) 55.1 (16,623)
Male 45.5 (14,306) 59.0 (764) 44.9 (13,542)
Ethnicity
White 45.2 (14,225) 48.5 (629) 45.1 (13,596)
Black or African American 27.8 (8,758) 39.0 (506) 27.4 (8,252)
Asian 2.5 (791) 1.2 (16) 2.6 (775)
Native Hawaiian or other Pacific Islander 0.4 (115) 0.7 (9) 0.4 (106)
American Indian or Alaska Native 0.3 (96) 0 0.3 (96)
Unknown 23.8 (7,476) 10.5 (136) 24.3 (7,340)
Weighted Charlson comorbidity index
0 59.5 (18,734) 17.3 (224) 61.4 (18,510)
1 17.4 (5,458) 16.1 (208) 17.4 (5,250)
2 7.9 (2,473) 14.4 (187) 7.6 (2,286)
�3 15.2 (4,796) 52.2 (677) 13.7 (4,119)
Comorbidities within the Charlson comorbidity index
Myocardial infarction 4.1 (1,280) 20.2 (262) 3.4 (1,018)
Congestive heart failure 7.3 (2,297) 30.8 (399) 6.3 (1,898)
Peripheral vascular disease 5.1 (1,601) 18.2 (236) 4.5 (1,365)
Cerebrovascular disease 6.1 (1,922) 19.6 (254) 5.5 (1,668)
Dementia 3.3 (1,031) 15.4 (199) 2.8 (832)
Chronic pulmonary disease 17.5 (5,513) 30.2 (391) 17.0 (5,122)
Rheumatic disease 2.2 (681) 4.2 (54) 2.1 (627)
Peptic ulcer disease 1.4 (432) 2.9 (37) 1.3 (395)
Mild liver disease 4.8 (1,497) 9.3 (121) 4.6 (1,376)
Moderate/severe liver disease 0.4 (138) 1.7 (22) 0.4 (116)
Diabetes mellitus 15.0 (4,710) 32.4 (420) 14.2 (4,290)
Hemiplegia or paraplegia 1.3 (421) 3.0 (39) 1.3 (382)
Renal disease 8.7 (2,735) 37.5 (486) 7.5 (2,249)
Any malignancya 6.3 (1,966) 14.8 (192) 5.9 (1,774)
Metastatic solid tumor 1.2 (383) 3.9 (51) 1.1 (332)
AIDS/HIV 0.7 (226) 1.3 (17) 0.7 (209)
Results are % (n) unless otherwise stated.
aAny malignancy, including lymphoma and leukemia, except malignant neoplasm of skin. Comorbidities are based on ICD-10 codes from 2015.
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range.
https://doi.org/10.1371/journal.pmed.1003321.t001
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multivariate analyses. When examining comorbidities, history of myocardial infarction
and renal disease were associated with higher odds of death for all age groups, but there were
differences across age groups for other comorbidities and associations with mortality. For peo-
ple aged<50 years, history of mild liver disease and any malignancy were associated with
higher odds of death. For people aged 50–69 years, history of congestive heart failure, chronic
pulmonary disease, moderate/severe liver disease, metastatic solid tumor, and AIDS/HIV were
all associated with higher odds of death. For people aged 70–90 years, history of congestive
heart failure and dementia were associated with higher odds of death (S1 Table, S2 Table and
S3 Table).
Discussion
In this retrospective cohort study, we identified 31,461 adults with confirmed COVID-19 from
EMRs from 24 healthcare organizations in the US between January 20, 2020, and May 26,
2020. Older age, male sex, black or African American ethnicity, and a history of myocardial
Table 2. Unadjusted and multivariate analysis of factors associated with mortality in adults with COVID-19 coded in the TriNetX research network as of May 26,
2020 (n = 31,461).
Unadjusted results Multivariate results
Characteristics Death with COVID-19, OR (95% CI) p-Value Death with COVID-19, OR (95% CI) p-Value
Age (per year) 1.074 (1.069–1.078) <0.001 1.063 (1.058–1.068) <0.001
Male sex 1.76 (1.57–1.97) <0.001 1.75 (1.55–1.98) <0.001
Ethnicity
White Ref Ref
Black or African American 1.33 (1.18–1.49) <0.001 1.50 (1.31–1.71) <0.001
Asian 0.45 (0.27–0.74) 0.002 0.60 (0.36–1.01) 0.06
Native Hawaiian or other Pacific Islander 1.84 (0.92–3.64) 0.09 3.63 (1.75–7.52) 0.001
American Indian or Alaska Native - - - -
Unknown 0.40 (0.33–0.48) <0.001 0.74 (0.60–0.90) 0.003
Comorbidities within the Charlson comorbidity index
Myocardial infarction 7.25 (6.25–8.42) <0.001 1.97 (1.64–2.35) <0.001
Congestive heart failure 6.62 (5.84–7.52) <0.001 1.42 (1.21–1.67) <0.001
Peripheral vascular disease 4.70 (4.04–5.46) <0.001 0.89 (0.74–1.07) 0.20
Cerebrovascular disease 4.16 (3.60–4.82) <0.001 1.07 (0.90–1.28) 0.44
Dementia 6.40 (5.42–7.55) <0.001 1.29 (1.07–1.56) 0.008
Chronic pulmonary disease 2.11 (1.87–2.39) <0.001 1.24 (1.08–1.43) 0.003
Rheumatic disease 2.05 (1.54–2.72) <0.001 1.17 (0.85–1.60) 0.16
Peptic ulcer disease 2.21 (1.57–3.12) <0.001 0.76 (0.52–1.12) 0.21
Mild liver disease 2.15 (1.77–2.62) <0.001 1.26 (1.00–1.59) 0.046
Moderate/severe liver disease 4.47 (2.83–7.08) <0.001 2.62 (1.53–4.47) <0.001
Diabetes mellitus 2.89 (2.56–3.26) <0.001 1.11 (0.96–1.27) 0.16
Hemiplegia or paraplegia 2.42 (1.73–3.38) <0.001 0.76 (0.52–1.09) 0.14
Renal disease 7.45 (6.60–8.40) <0.001 2.13 (1.84–2.46) <0.001
Any malignancy 2.78 (2.37–3.27) <0.001 0.87 (0.72–1.06) 0.17
Metastatic solid tumor 3.68 (2.73–4.97) <0.001 1.70 (1.19–2.43) 0.004
AIDS/HIV 1.91 (1.16–3.13) 0.011 1.71 (1.00–2.93) 0.051
American Indian or Alaska Native omitted because there were no deaths among this group. Only characteristics p< 0.05 in the unadjusted analyses were included in
the multivariate analysis.
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003321.t002
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infarction, congestive heart failure, dementia, chronic pulmonary disease, mild liver disease,
moderate/severe liver disease, renal disease, and metastatic solid tumor were associated with
higher odds of mortality after adjustment for these factors and other comorbidities.
Older age has been frequently reported to be an important factor associated with disease
severity or mortality in patients with COVID-19 [4–6]. There is some previous evidence to
suggest men, people who are black or African American, or people from certain ethnic minor-
ity backgrounds may also be higher risk for COVID-19 [7–10]. Underlying comorbidities
including preexisting concurrent cardiovascular or cerebrovascular diseases, hypertension,
and diabetes mellitus have been reported as highly prevalent in studies of COVID-19 patients
and/or associated with poorer outcomes for these patients [5, 7, 11]. This study further sug-
gests that cardiovascular conditions such as previous myocardial infarction or congestive heart
failure may be important factors influencing mortality in patients with COVID-19. Further-
more, a recent meta-analysis of 4 studies suggested chronic kidney disease may be associated
with enhanced risk of severe COVID-19 infection [12]. The results of this study agree with a
recent UK-based cohort study that showed an association between older age, male sex, cardiac
disease, non-asthmatic pulmonary disease, kidney disease, liver disease, malignancy, and
dementia and higher mortality in hospital for patients with COVID-19 [19]. The UK-based
study also showed an association between obesity and higher mortality, which could not be
explored in the current study because of a paucity of data on body mass index.
Age-stratified analyses in the current study highlighted the potential importance of consid-
ering age groups when examining associations between comorbidities and mortality with
COVID-19. We found a history of myocardial infarction or renal disease to be associated with
mortality in all age groups, but there were differences found between age groups for which
other comorbidities associated with mortality. In this study, a borderline association was
found in this study between AIDS/HIV and mortality with COVID-19 when examining all
adults, but age-stratified analyses suggested AIDS/HIV was associated with significantly higher
odds of mortality only in people aged 50–69 years. Patients with AIDS/HIV represented a
small proportion of the total patient population, and larger studies of patients with AIDS/HIV
and COVID-19 are needed to further determine the association. The findings in this study of
an association between liver disease and mortality for patients with COVID-19 are in line with
a recently published study that used data from TriNetX and showed patients with preexisting
liver disease had a higher risk of mortality with COVID-19 [20].
Limitations
This study has several limitations. The data were collected from healthcare organization EMR
databases and some comorbidities may be underreported, and ethnicity was not available for
all participants. Residual confounding may include lifestyle factors and socioeconomic status,
which were not available from EMRs. Body mass index was only available for approximately
5% of participants and so was not included in analyses. We could also not determine the influ-
ence of attending different healthcare organizations, owing to data privacy restrictions. In
these analyses, we found a significant association between those with “unknown” ethnicity
from EMRs and reduced odds of death compared to white patients. Participants with
unknown ethnicity may have been participants who did not fit in the limited prespecified eth-
nicity categories within TriNetX, but this could not be explored further, given restrictions on
data privacy. Only age at death, not date of death, was available in downloaded data, so time-
to-event analyses could not be performed. Participants who died with COVID-19 after the
study end date would have been recorded as alive in the present analyses, and deaths outside of
the participating healthcare organizations are not well captured. The data in EMRs are
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susceptible to errors in coding or data entry when patient information is translated to ICD
codes. In this study, we looked at any history of the comorbidities identified in the Charlson
comorbidity index since 2015. We could not determine if the patient was no longer living with
the condition. Recording of ICD codes in administrative data may vary by factors such as age,
number of comorbidities, severity of illness, length of hospitalization, and whether in-hospital
death occurred [21]. The data were from multiple healthcare organizations in the US but may
not be representative of the wider US population, and the generalizability of the results beyond
this cohort is unclear.
Conclusions
Increasing age, being male, being black or African American compared to white, and a history
of myocardial infarction, congestive heart failure, dementia, chronic pulmonary disease, liver
disease, renal disease, and metastatic solid tumor were associated with mortality in adults with
COVID-19. There were differences in which comorbidities were associated with higher odds
of mortality depending on age group.
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